Home › NDC Lookup › RxCUI directory › RxCUI 903847

Pyridostigmine bromide 180 MG Extended Release Oral Tablet — RxCUI 903847

RxNorm drug concept · Semantic clinical drug
RxCUI 903847 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI903847
Official namePyridostigmine bromide 180 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)3,913 prescriptions · 29 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pyridostigmine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Mestinon and the oral solution treat myasthenia gravis. Regonol is a hospital injection that reverses muscle relaxants. Other tablets are for military us...
  • Take it exactly as prescribed. Oral products are swallowed, and doses are adjusted to your needs and spaced through the day. The military extended-release tablet must be taken with...
  • Stomach upset is most common, including diarrhea, cramps and nausea. Some people notice twitching, sweating or drooling. These come from extra acetylcholine activity, so tell your...
  • Get help right away for trouble breathing, severe dizziness, fainting, or growing muscle weakness. These can be signs of a serious reaction or too much medicine.
📖 Read our full Pyridostigmine guide →

🕸️ Concept Web — How Pyridostigmine bromide 180 MG Extended Release O... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pyridostigmine bromide 180 MG Extended Release Oral Tablet RxCUI 903847

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Pyridostigmine 9000
    • Pyridostigmine bromide 9001
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mestinon 203001
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pyridostigmine Extended Release Oral Tablet 373707
    • Pyridostigmine bromide Extended Release Oral Tablet 2647651
    • Pyridostigmine Oral Product 1163606
    • Pyridostigmine Pill 1163607
    • Pyridostigmine bromide Oral Product 2659335
    • Pyridostigmine bromide Pill 2661344
    • Pyridostigmine Extended Release Oral Tablet [Mestinon] 687192
    • Pyridostigmine bromide Extended Release Oral Tablet [Mestinon] 2658213
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pyridostigmine bromide 180 MG SCDC · 903846
  • Pyridostigmine Extended Release Oral Tablet SCDF · 373707
  • Pyridostigmine bromide Extended Release Oral Tablet SCDFP · 2647651
  • Pyridostigmine Oral Product SCDG · 1163606
  • Pyridostigmine Pill SCDG · 1163607
  • Pyridostigmine bromide Oral Product SCDGP · 2659335
  • Pyridostigmine bromide Pill SCDGP · 2661344

Brand-Name Concepts

  • Pyridostigmine bromide 180 MG Extended Release Oral Tablet [Mestinon] SBD · 903849
  • Pyridostigmine bromide 180 MG [Mestinon] SBDC · 903848
  • Pyridostigmine Extended Release Oral Tablet [Mestinon] SBDF · 687192
  • Pyridostigmine bromide Extended Release Oral Tablet [Mestinon] SBDFP · 2658213
  • Mestinon Oral Product SBDG · 1185042
  • Mestinon Pill SBDG · 1185043
  • Mestinon BN · 203001

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 903847 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00187-3010-30 100 TABLET in 1 BOTTLE (0187-3010-30) Mestinon Bausch Health US, LLC 1995-04-06
00187-3012-20 473 mL in 1 BOTTLE (0187-3012-20) Mestinon Bausch Health US, LLC 1965-01-25
00187-3013-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-3013-30) Mestinon Bausch Health US, LLC 1959-01-12
47781-0335-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47781-335-30) Pyridostigmine Bromide Alvogen, Inc. 2015-06-29
64980-0220-03 30 TABLET in 1 BOTTLE (64980-220-03) Pyridostigmine Bromide Rising Pharma Holdings, Inc. 2017-08-15
68682-0301-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68682-301-30) pyridostigmine bromide Oceanside Pharmaceuticals 1959-01-12
Observed labelers: Bausch Health US, LLC (3) · Alvogen, Inc. (1) · Oceanside Pharmaceuticals (1) · Rising Pharma Holdings, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.